arrow
S

Sven Almér

karolinska institutet
H指数:57
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH study

vedolizumab治疗的炎症性肠病患者医疗资源利用和生产损失:来自瑞典前瞻性多中心SVEAH研究的结果

2025-07-170
OA
Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes
2023-09-284
OA
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

维多珠单抗治疗炎症性肠病的长期结果: 瑞典前瞻性多中心SVEAH扩展研究

2023-05-302
OAAI
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
2023-03-0140
OAAI
Detailed Transcriptional Landscape of Peripheral Blood Points to Increased Neutrophil Activation in Treatment-Naive Inflammatory Bowel Disease

外周血的详细转录景观表明在未经治疗的炎症性肠病中中性粒细胞活化增加

2022-01-1111
OAAI
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study

vedolizumab在炎症性肠病中的实际疗效: 来自瑞典前瞻性多中心SVEAH研究的52周结果

2021-07-0321
OAAI
Association Between Collagenous and Lymphocytic Colitis and Risk of Severe Coronavirus Disease 2019

胶原性和淋巴细胞性结肠炎与严重冠状病毒疾病风险之间的关联2019

2021-06-012
OAAI
Tissue-specific transcriptional imprinting and heterogeneity in human innate lymphoid cells revealed by full-length single-cell RNA-sequencing
2021-01-08117
OAAI
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
2020-09-0125
OAAI
Medical treatment and surgery in patients with elderly-onset inflammatory bowel disease: 3-year follow-up of Epi-IBD 2010-2011 cohorts
2019-01-250
OAAI
Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis
2017-06-01358
OAAI